跳至主要内容
临床试验/EUCTR2015-005110-30-IT
EUCTR2015-005110-30-IT进行中(未招募)1 期

A multicenter randomized trial to evaluate the efficacy of fentanyl pectin nasal spray (FPNS) versus Physician Choice (PC) - Usual Care (UC), in reducing incidental predictable breakthrough pain (IP-BTP) at swallowing in patients with head and neck cancer undergoing radiotherapy - FAST RELIEF

FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI0 个研究点目标入组 158 人开始时间: 2020年11月5日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
158

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1.Male and female aged 18 years or over
  • 2.Diagnosis of stage III-IV cancer of oral cavity, oropharynx, hypopharynx, larynx, salivary gland cancer.
  • 3.Receiving radiation therapy (RT) with or without concurrent platinum based chemotherapy or cetuximab as first line treatment or as postoperative adjuvant treatment
  • 4.Background pain managed with a stable fixed dose of opioid equivalent to 60mg oral morphine daily
  • 5.Uncontrolled pain (IP-BTP) during swallowing with an intensity =4 on an 11-point numeric scale (0=no pain; 10=worst possible pain). This pain will have to be measured with the ingestion of a solid/liquid food (depending on the ability to swallow or less solid foods of the patient at moment)
  • 6.Patients able to receive a nasal spray therapy
  • 7.Willing and able to sign an informed consent form
  • 8.Females with childbearing potential must provide a negative pregnancy test and both males and females must be using adequate contraception during the study
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 100
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 58

排除标准

  • 1.Patients with known metastatic disease.
  • 2.Known hypersensitivity to opioids, to Fentanyl or to drugs used in the PC-UC, and/or to study medications’ formulation ingredients.
  • 3.Patients with impaired chemistry laboratory exams, assessed as routine clinical practice before radiotherapy start:
  • a.Hepatic function:
  • i.Total bilirubin > 2 times the upper-normal limit (ULN)
  • ii.ii. Serum transaminase > 5 times ULN
  • b.Renal function:
  • i.Serum creatinine concentration > 2 times ULN
  • 4.Pregnant or breastfeeding women.
  • 5.Patients unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study.
  • 6.Patients planned to receive other investigational treatments during study period
  • 7.Patients with moderate to severe respiratory impairment
  • 8.Patients assuming one of the following drug that can interfere with fentanyl:
  • Monoamine Oxidase Inhibitors, IMAO)
  • Ritonavir, ketoconazol, Itraconazolo, Troleandomicina, Claritromicina and Nelfinavir
  • Nasal decongestants

研究者

相似试验